Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

被引：0
|
作者：
T M Beer
D C Smith
A Hussain
M Alonso
J Wang
M Giurescu
K Roth
Y Wang
机构：
[1] Knight Cancer Institute,
[2] Oregon Health & Science University,undefined
[3] University of Michigan Health System,undefined
[4] University of Maryland Medical Center,undefined
[5] Marlene and Stewart Greenebaum Cancer Center,undefined
[6] Private Hospital of Córdoba,undefined
[7] University of Nebraska Medical Center,undefined
[8] Bayer HealthCare Pharmaceuticals,undefined
[9] Astellas Pharma Global Development,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
clinical trial; phase II; epothilones; prednisone; prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：808 / 813
页数：5
相关论文
共 50 条
  • [21] Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC)
    Graff, J.
    Smith, D. C.
    Neerukonda, L.
    Alonso, M.
    Jones, G. R.
    Beer, T. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials consortium
    Scher, H.
    Beer, T.
    Higano, C.
    Logothetis, C.
    Shelkey, J.
    Hung, D.
    Hirmand, M.
    Larson, S.
    Fleisher, M.
    Sawyers, C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 51 - 52
  • [23] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
    Mahammedi, H.
    Pouget, M.
    Planchat, E.
    Cure, H.
    Durando, X.
    Van-Praagh, I.
    Savareux, L.
    Abrial, C.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [24] Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
    Caffo, Orazio
    Ortega, Cinzia
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Facchini, Gaetano
    Veccia, Antonello
    Palesandro, Erica
    Verri, Elena
    Buti, Sebastiano
    Razzini, Giorgia
    Bozza, Giovanni
    Maruzzo, Marco
    Ciccarese, Chiara
    Schepisi, Giuseppe
    Rossetti, Sabrina
    Maines, Francesca
    Kinspergher, Stefania
    Fratino, Lucia
    Ermacora, Paola
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Sabbatini, Roberto
    Lo Re, Giovanni
    Morelli, Franco
    D'Angelo, Alessandro
    Vittimberga, Isabella
    Lippe, Paolo
    Carrozza, Francesco
    Messina, Caterina
    Galli, Luca
    Valcamonico, Francesca
    Porta, Camillo
    Pappagallo, Giovanni
    Aglietta, Massimo
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 56 - 63
  • [25] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [26] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [27] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [28] Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Rathkopf, Dana E.
    Danila, Daniel Costin
    Morris, Michael J.
    Slovin, Susan F.
    Steinbrecher, Jill Elise
    Arauz, Gabrielle
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Fox, Josef J.
    Fleisher, Martin
    Larson, Steven M.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [29] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
    Danila, Daniel C.
    Morris, Michael J.
    de Bono, Johann S.
    Ryan, Charles J.
    Denmeade, Samuel R.
    Smith, Matthew R.
    Taplin, Mary-Ellen
    Bubley, Glenn J.
    Kheoh, Thian
    Haqq, Christopher
    Molina, Arturo
    Anand, Aseem
    Koscuiszka, Michael
    Larson, Steve M.
    Schwartz, Lawrence H.
    Fleisher, Martin
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1496 - 1501
  • [30] The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer
    Scher, H. I.
    Halabi, S.
    Tannock, I.
    Morris, M.
    Higano, C.
    Kelly, W.
    Sternberg, C.
    Eisenberger, M.
    Martin, A.
    Hussain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345